Vernalis PLC Block listing Interim Review (2594A)

TIDMVER

RNS Number : 2594A

Vernalis PLC

29 March 2017

BLOCK LISTING SIX MONTHLY RETURN AND BLOCK LISTING APPLICATION

VERNALIS PLC (the "Company")

29 March 2017

Vernalis plc (LSE: VER) provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements:

 
 Name of applicant:            Vernalis plc 
----------------------------  ------------------------------------------------- 
 Name of scheme(s):            2007 Long Term Incentive 
                                Scheme ("LTIP") and 2016 
                                Executive Incentive Plan 
                                ("EIP") 
----------------------------  ------------------------------------------------- 
 Period of return              From: 29/Sept/2016         To: 29/March/2017 
  (from / to): 
----------------------------  -------------------------  ---------------------- 
 Balance of unallotted         Total of 401,056 Ordinary 
  securities under              1p Shares under LTIP 
  scheme(s) from previous 
  return: 
----------------------------  ------------------------------------------------- 
 Plus: The amount              Total of 499,612 Ordinary 
  by which the block            1p Shares, split: 
  scheme(s) has been             *    Under LTIP = 199,026 Ordinary 1p Shares 
  increased or application 
  has been made to 
  increase since the             *    Under EIP = 300,586 Ordinary 1p Shares 
  date of the last 
  return (if any increase 
  has been applied              As applied for in the 
  for):                         below paragraph. 
----------------------------  ------------------------------------------------- 
 Less: Number of securities    Total of 163,876 Ordinary 
  issued/allotted under         1p Shares under LTIP 
  scheme(s) during 
  period: 
----------------------------  ------------------------------------------------- 
 Less: Number of securities    Total of 8,001 Ordinary 
  forfeited under scheme(s)     1p Shares under LTIP 
  during period: 
----------------------------  ------------------------------------------------- 
 Equals: Balance under         Total of 728,791 Ordinary 
  scheme(s) not yet             1p Shares, split: 
  issued/allotted at             *    Under LTIP = 428,205 Ordinary 1p Shares 
  end of period: 
 
                                 *    Under EIP = 300,586 Ordinary 1p Shares 
----------------------------  ------------------------------------------------- 
 Number and class               No. of       Date on which 
  of securities originally        Ordinary     Shares were Admitted 
  admitted and the                1p Shares    to Trading 
  date of admission             -----------  ---------------------- 
  (including any additions):     350,000      6 November 2013, 
                                               plus 
                                -----------  ---------------------- 
                                 1,049,317    12 May 2014, 
                                               plus 
                                -----------  ---------------------- 
                                 1,058,184    12 May 2015, 
                                               plus 
                                -----------  ---------------------- 
                                 1,638,364    30 September 
                                               2015 
                                -----------  ---------------------- 
                                 1,189,296    1 April 2016 
                                -----------  ---------------------- 
                                 499,612      31 March 2017 
                                -----------  ---------------------- 
----------------------------  ------------------------------------------------- 
 

BLOCK LISTING APPLICATION

Vernalis plc announces that application has been made to the London Stock Exchange for the admission of 499,612 Ordinary Shares of 1 pence each (the "Ordinary Shares") in the Company under the Company's existing block listing scheme. These Ordinary Shares will be available to satisfy future exercises of options over Ordinary Shares under the Company's employee share schemes being: the LTIP; and the EIP. It is expected that admission will become effective on 31 March 2017. When issued, these shares will rank pari passu with the existing Ordinary Shares.

-- ends -

Enquiries:

 
                                   [phone] 
 Vernalis plc:                                0015 
 Ian Garland, Chief Executive 
  Officer 
 David Mackney, Chief Financial 
  Officer 
 Canaccord Genuity Limited 
  (Nominated Adviser and Joint     [phone] 
  Broker):                                    8000 
 Henry Fitzgerald-O'Connor 
 Emma Gabriel 
                                   [phone] 
 Shore Capital (Joint Broker):                4090 
 Bidhi Bhoma 
 Toby Gibbs 
                                   [phone] 
 FTI Consulting:                              1000 
 Ben Atwell 
 Simon Conway 
 Stephanie Cuthbert 
 

Notes to Editors

About Vernalis

Vernalis is a revenue generating, commercial stage pharmaceutical company with significant expertise in drug development. The Group has three approved products: Tuzistra(R) XR targeting the US prescription cough-cold market; Moxatag(R) , a once-daily formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatric patients 12 years and older; and frovatriptan for the acute treatment of migraine. It has an exclusive licensing agreement to develop and commercialise multiple novel products focused on the US prescription cough-cold market as well as eight programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including Asahi Kasei Pharma, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris.

For further information about Vernalis, please visit www.vernalis.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

BLRJTMLTMBATBFR

(END) Dow Jones Newswires

March 29, 2017 04:00 ET (08:00 GMT)